Editas Medicine, Inc. (EDIT) Insider Sells $196,992.12 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of Editas Medicine stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $23.64, for a total value of $196,992.12. Following the transaction, the insider now owns 1,393,322 shares of the company’s stock, valued at $32,938,132.08. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Katrine Bosley also recently made the following trade(s):

  • On Monday, October 2nd, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $24.78, for a total value of $206,491.74.
  • On Friday, September 1st, Katrine Bosley sold 10,000 shares of Editas Medicine stock. The stock was sold at an average price of $20.42, for a total value of $204,200.00.
  • On Tuesday, September 5th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.33, for a total value of $338,819.78.
  • On Friday, August 11th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.02, for a total value of $333,653.32.

Shares of Editas Medicine, Inc. (NASDAQ EDIT) traded up $1.56 during midday trading on Friday, reaching $24.93. The company’s stock had a trading volume of 972,339 shares, compared to its average volume of 921,432.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative net margin of 2,091.36% and a negative return on equity of 67.75%. Editas Medicine’s revenue was down 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.54) earnings per share. equities research analysts predict that Editas Medicine, Inc. will post -2.88 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/03/editas-medicine-inc-edit-insider-sells-196992-12-in-stock.html.

EDIT has been the subject of several research reports. ValuEngine cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Zacks Investment Research cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Cann initiated coverage on Editas Medicine in a report on Monday, July 17th. They set a “market perform” rating for the company. J P Morgan Chase & Co set a $27.00 price target on Editas Medicine and gave the stock a “hold” rating in a report on Wednesday, August 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $28.00 price target (up from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $25.88.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. IHT Wealth Management LLC acquired a new position in Editas Medicine in the 2nd quarter valued at $107,000. Royal Bank of Canada raised its holdings in Editas Medicine by 4.1% in the 2nd quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock valued at $157,000 after acquiring an additional 372 shares in the last quarter. Bank of America Corp DE raised its holdings in Editas Medicine by 72.2% in the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock valued at $133,000 after acquiring an additional 2,489 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Editas Medicine by 8.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 42,150 shares of the company’s stock valued at $941,000 after acquiring an additional 3,249 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in Editas Medicine by 18.9% in the 2nd quarter. ProShare Advisors LLC now owns 24,211 shares of the company’s stock valued at $406,000 after acquiring an additional 3,857 shares in the last quarter. 70.45% of the stock is owned by hedge funds and other institutional investors.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

What are top analysts saying about Editas Medicine Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Editas Medicine Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit